All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
What are the factors guiding treatment decisions for transplantation in MF?
Featured:
Francesco PassamontiDuring the 25th Congress of the European Hematology Association (EHA), the MPN Hub spoke to Francesco Passamonti, University of Insubria, Varese, IT. We asked: What are the factors guiding treatment decisions for transplantation in myelofibrosis?
There have been a number of different models designed to assist treatment decisions in myelofibrosis. Here, Francesco Passamonti outlines these parameters and how they are used in clinical practice to determine those patients put forward for stem cell transplant. Major considerations include the probability of survival and non-relapse mortality.
What are the factors guiding treatment decisions for transplantation in MF?